A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy

Background: In this single-arm phase II study (NCT03557099), we evaluated the efficacy and safety of hetrombopag, a small molecule thrombopoietin (TPO) receptor agonist, in patients with severe aplastic anemia (SAA) who were refractory to standard first-line immunosuppressive therapy (IST). Methods:...

Full description

Bibliographic Details
Main Authors: Guangxin Peng, Guangsheng He, Hong Chang, Sujun Gao, Xinjian Liu, Tong Chen, Pei Li, Bing Han, Miao Miao, Zheng Ge, Xiaoyan Ge, Fei Li, Yingmei Li, Shunqing Wang, Yi Wang, Yaqi Shen, Tao Zhang, Jianjun Zou, Fengkui Zhang
Format: Article
Language:English
Published: SAGE Publishing 2022-03-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207221085197

Internet

https://doi.org/10.1177/20406207221085197

Similar Items